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Abstract
Replacement of the insulin-secreting beta cells through transplantation of pancreatic islets to the liver is a promising treatment
for type-1 diabetes. However, low oxygen tension, shear stress, and the induction of inflammation lead to significant islet
dysfunction and loss. The anterior chamber of the eye (ACE) has gained considerable interest and represents an alternative
therapeutic islet transplantation site because of its accessibility, high oxygen tension, and immune-privileged milieu. We have
previously demonstrated the feasibility of intraocular islet transplant in mouse and nonhuman primate models of type-1 diabetes
and are now assessing its efficacy on glucose homeostasis in a nonhuman primate model of type-2 diabetes. We transplanted
allogeneic donor islets (1,500 islet equivalents/kg) into the anterior chamber of one eye in a cynomolgus monkey with high-fat-
diet-induced type-2 diabetes. Repeated examinations of the anterior and posterior segments of both eyes were done to monitor
the engrafted islets and assess the overall ocular health. Fasting blood glucose level, blood biochemistry, and other metabolic
parameters were routinely evaluated to determine the function of the islet graft and diabetes status. The transplanted islets were
rapidly engrafted onto the iris and became vascularized 1 month after transplantation. We did not detect changes in intraocular
pressure, cataract formation, ophthalmitis, or retinal vessel deformation. A significant lower fasting blood glucose level was
observed while the graft was in place, and the transplantation reverts the progression of diabetes. The metabolic markers,
hemoglobin A1C and fructosamine, demonstrated improvement following islet transplantation. As a conclusion, intraocular islet
transplantation in one eye of a cynomolgus monkey with type-2 diabetes improved its overall plasma glucose homeostasis, as
evidenced by short-term measures and long-term metabolic markers. These results further support the future application of the
ACE as an alternative site for clinical islet transplants in the context of type-2 diabetes.
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Introduction
Diabetes is among the leading causes of death, and its global
prevalence of 425 million people in 2017 is expected to rise
to 629 million in 20451. Patients with diabetes are at high
risk of macro- and micro-vascular pathologies leading to
cardiovascular diseases and diabetes-associated retinopathy,
neuropathy, and nephropathy2. Poorly controlled glycemia
rapidly leads to serious health complications such as kidney
failure, blindness, and lower limb amputation. The key fac-
tor in preventing these complications is mainly dependent on
timely and persistent glycemic control through lifestyle
changes, antidiabetic medications, and insulin therapy when
needed3,4. Transplantation of isolated pancreatic islets has
emerged as a promising therapy in type-1 diabetes and pro-
ven to reduce the exogenous insulin dependency5–7. How-
ever, limited information is available for the transplantation
of islets in type-2 diabetes. The hepatic portal vein is cur-
rently the site of choice for clinical islet transplantation.
However, liver-specific complications such as low oxygen
tension, shear stress, high enzymatic activity, local drug lev-
els, and the induction of immediate blood-mediated inflam-
matory reaction (IBMIR) lead to significant islets loss
immediately after transplantation and islet grafts dysfunction
over time. A substantial surplus of transplanted islets is
required to compensate for this immediate loss, and the same
patient may need to undergo several islet transplantations
over time (i.e., involving several donors) to achieve indepen-
dence from exogenous insulin6–10. Therefore, the search for
alternative islet transplantation sites remains a priority.
The anterior chamber of the eye (ACE) has gained con-
siderable interest and represents a promising new site for
therapeutic islet transplantation because of its high oxygen
tension and immune-privileged milieu, among other techni-
cal advantages. Major advantages of the ACE as a transplan-
tation site compared to other sites include less invasive
surgery for introducing islets11,12, a smaller number of
islets is required per body weight to improve glycemic
control12–15, enhanced accessibility to islet grafts with the
optically transparent cornea whereby allowing noninvasive
and longitudinal high-resolution monitoring of islet
grafts11,14–18, high potential for local immunosuppression19,
and the possibility for systemic tolerization through anterior
chamber-associated immune deviation20. We report here a
first-of-its-kind case study of a type-2 diabetic nonhuman
primate with sustained improvement in its glycemia and
overall metabolic control following islet transplantation into
the anterior chamber of one eye.
Materials and Methods
Husbandry and Handling of the Animal
The experiments were done in accordance with the guide-
lines and approval from the Institutional Animal Care and
Use Committee (IACUC), SingHealth, Singapore. The ani-
mal was sourced from PT. Prestasi Fauna Nusantara Ltd,
Jakarta, Indonesia, and it was housed in a 2 in 1 tier stainless
steel cage with ad libitum access to water through the auto-
matic watering system. Enrichment toys were provided, and
fruits were given every day as treats. Parasite check, supple-
ment administration, deworming, random bacterial culture,
methicillin-resistant Staphylococcus aureus screening, and
in-depth physical assessment of the animal were conducted
semiannually. In general, National Advisory Committee for
Laboratory Animal Research (NACLAR) guidelines were
adhered to for the housing condition. The monkey was
sedated for surgeries and imaging procedures according to
the guidelines using intramuscular ketamine, and isoflurane
gas was used at 3%–5% for induction and 1%–2% for main-
tenance. Heart rate, respiratory rate, and temperature were
monitored throughout the procedures.
Induction of Type-2 Diabetes and Experimental Design
There are limited literature and dearth of robust protocols for
type-2 diabetes induction in macaque monkeys. Here we
report on a macaque with type-2 diabetes following 5 years
of exposure to high-fat diet. Type-2 diabetes was induced in
a 15-year-old male cynomolgus monkey (Macaca fascicu-
laris) by giving 13% high-fat diet (LabDiet, St. Louis, MO,
USA) for 5 years (Fig. 1). After the development of diabetes,
the plasma blood glucose level of the monkey was monitored
twice a day, once in the morning as fasting level before the
meal and once in the afternoon before the enrichment fruits
were given, by tail prick using an Accu-Chek hand-held
glucometer (Roche, Basel, Switzerland). Allogeneic islet
transplantation into the ACE was done on post operation day
(POD) 0. The animal was given transient systemic therapy
with an anti-CD154/CD40 L monoclonal antibody (clone
5C8) in the peri-transplant period at PODs -1, 0, 3, 10, 18,
28, 56, and 84. The efficacy of the islet graft was evaluated
by different parameters over the experimental period, such
as daily blood glucose level, twice a month fructosamine,
monthly hemoglobin A1C (HbA1C), bimonthly intra-venous
glucose tolerance tests (IVGTTs), and C-peptide analysis in
the aqueous humor. IVGTT was performed by giving a
0.5 g/kg body weight bolus dose of glucose intravenously,
and the plasma glucose was assessed at predetermined
intervals up to 90 min after the glucose injection.
Islet Isolation and Transplantation of the Islets
into the ACE
The islets were isolated as previously described11,21. In brief,
the islets were isolated from the whole pancreas of a healthy
donor cynomolgus monkey, using the liberase enzyme in a
Ricordi chamber followed by purification with Ficoll gradi-
ents. The islets were cultured for 2 days before transplanta-
tion. We performed glucose-stimulated insulin secretion
(GSIS) assay on the isolated islets as a quality assessment
and a stimulation index of 2.98 was measured. The isolated
islets were then transplanted into the ACE of the recipient
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type-2 diabetic monkey (Fig. 2A). The transplant was done
under sterile conditions in an operating room. One drop of a
miotic agent, 3% pilocarpine (Alcon, Geneva, Switzerland),
was instilled into the left eye of the primate half an hour
before transplantation, letting the pupil constrict to have a
maximum space of the iris bed. The peri-ocular regions were
sterilized with povidone-iodine, followed by washing with
physiological saline. A self-sealing incision was made on the
clear cornea using a disposable 23G needle, 3 mm away
from the cornea–sclera junction at the temporal quadrant.
We transplanted a total of 12,000 islets (1,500 islet equiva-
lents/kg) into the left eye only as a metabolic transplant. The
isolated islets were withdrawn into a customized 25G thin-
walled blunt cannula attached to a polyethylene tubing and
held upward to let the islets settle down by gravity for 3 min.
The cannula was then inserted into the pre-made self-sealing
incision, and the islets were injected slowly into the ACE
over 5 min while letting out the excess fluids from the eye
via the entry incision. Total fluid injected together with the
islets was expected to be around 150 ml. An air bubble was
created at the center to prevent the islets from settling on the
pupil. The cells were equally distributed over the whole iris
by gently moving the eye. The animal was put in a supine
position with the head facing upward for 2 hr, giving the
transplanted islets time to attach to the iris. One drop of
0.5% levofloxacin (Cravit, Santen Pharmaceutical, Osaka,
Japan) was instilled immediately after the procedure.
Iridectomy
To show the effect of the transplanted islets on blood glucose
homeostasis, we removed the engrafted islets together with
the iris on POD 186. The surgery was done under sterile
condition in the operation room. Peri-ocular region and con-
junctival sac of the surgery eye were cleaned with a standard
ocular sterilization procedure. Peripheral corneal
paracentesis 2–3 mm was made at 12 o’clock position using
a sterile disposable 2.8 mm slit blade (NANOedge Ophthal-
mic blades, Madhu Instruments Pvt. Ltd, New Delhi, India)
without injuring the iris. The disposable 25G end-grasping
forceps (Alcon) was inserted into the ACE, and the iris was
then grabbed and pulled slowly to detach from the trabecular
meshwork before extracting the whole iris out from the para-
centesis (Fig. 2B, C). The incision was closed using a 10
suture, and topical antibiotic/steroids, 0.3% tobramycin, and
0.1% dexamethasone (Tobradex ointment, Alcon) were
given for 3 days to prevent infection.
Ophthalmological Examinations
The intraocular pressure (IOP) was assessed using a Tono-Pen
AVIA Vet Veterinary Tonometer (Reichert Technologies,
Depew, NY, USA) after the instillation of a drop of 1% ligno-
caine. The graft and the anterior portion of the eye were exam-
ined by a standard slit-lamp examination. The posterior portion
of the eye, retinal fundus images, retinal nerve fiber layer
(RNFL), and retinal thickness were evaluated using Spectralis
(Heidelberg Retinal Tomography, Heidelberg, Germany).
Analysis
All data were plotted and analyzed using GraphPad Prism
version 6.03 (GraphPad Software, CA, USA). The data
shown are mean + SD, and a nonparametric Kruskal–Wallis
test was used to compare the groups. P value  0.05 was
considered significant. The area under the curve (AUC) and
frequency distribution curve were developed using the same
software. All data points from the pre-transplant period
(POD –101 to POD 0), post-transplantation period (POD
97 to POD 185), and data from the post-iridectomy period
(POD 186 to POD 348) were used for analysis. We excluded
data from POD 0 to 96 to rule out the full engraftment and
Figure 1. Experimental design. Isolated islets (1,500 islet equivalents/kg) from a healthy donor were transplanted into the anterior chamber
of the eye (ACE) of a high-fat-diet-induced type-2 diabetic monkey. Peri-transplantation immunosuppression with anti-CD154 was given at
PODs -1, 0, 3, 10, 18, 28, 56, and 84. Fasting blood glucose level, blood biochemistry, and metabolic parameters were evaluated for the graft
function comparing the pre-transplant period, post-transplant period, and post-iridectomy period.
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vascularization interval, and to exclude results from the
unexpected tail injury period.
Results
Changes in Glycemia in a High-Fat-Diet-Fed Macaque
The plasma glucose level consistently rose above 5 mmol/l
for three consecutive time points during monthly surveil-
lance. Subsequently, the plasma blood glucose level was
monitored twice a day by tail prick method using an Accu-
Chek hand-held glucometer (Roche, Indianapolis, IN, USA).
The monkey was not under any diabetic medication or
insulin therapy throughout the experiment. Following trans-
plantation, there was a nontransplantation-related inflicted
tail injury from POD 60 to POD 96, and the glucose level
became erratic during this period, most likely due to the
influence of pain and adrenaline. The monkey was given
more recreational tools to reduce stress. The tail injury was
fully recovered at POD 96 with appropriate wound and pain
management by qualified veterinarians. There was a slight
bodyweight drop by 350 g after the transplantation from
8 kg, which was further decreased to 6.7 kg after removal
of the graft.
Figure 2. Visualization of islet graft and total iridectomy. (A) A total of 1,500 islet equivalents/kg were transplanted into the anterior
chamber of the eye (ACE) of a high-fat-diet-induced type-2 diabetic monkey. The engraftment was confirmed by direct slit-lamp examination
and OCT imaging of the iris at 1 month and 6 months (before removal of the graft) post-transplantation. The areas indicated by yellow
dotted line are the engrafted islets on the iris in the ACE of the monkey. (B) The whole iris engrafted with transplanted islets was removed
on POD 186 to show the effect of the graft on blood glucose homeostasis. (C) After the removal of the iris showing the absence of engrafted
islets. POD: post operation day.
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Intraocular Islet Transplantation Had No Impact on
the Eye Anatomy in the Anterior or Posterior Segments
Consistent with our prior observations11,12,15,16, the trans-
planted islets were visually confirmed to be engrafted and
revascularized on the iris 1 month after transplantation. The
graft was checked again by direct slit-lamp examination and
optical coherence tomography imaging 3 and 6 months
(before the iridectomy) after transplantation (Fig. 2A). There
was a cicatrization of the iris near the edge of the pupil at the
6 o’clock position due to islet aggregation, but no synechia
was formed. We performed a brief cage-side assessment for
vision using a flashlight to the transplanted eye to check the
behavioral response with no indication of affected vision.
We did not observe any change in IOP in both eyes through-
out the experiment (Table S1). There was no cataract forma-
tion, ophthalmitis, or retinal vessel deformation, and the
retinal thickness profile was within the normal range in the
transplanted eye. There was no apparent change in RNFL
thickness (Table S1).
Glycemic Control Was Improved Following Intraocular
Islet Transplantation in the Type-2 Diabetic Macaque
The mean fasting plasma glucose level at pre-transplantation
(5.6 + 0.1 mmol/l; n ¼ 96 measurements) was significantly
decreased (P ¼ 0.0001; 4.8 + 0.1 mmol/l; n ¼ 88 measure-
ments) post-transplantation. After the removal of the islet
graft by iridectomy, it was significantly increased to 6.3 +
0.1 mmol/l until the end of the experiment (n ¼ 144 mea-
surements; P < 0.0001; Fig. 3A). We also observed an
increase in the frequency of lower plasma glucose values
following transplantation (Fig. 4A–C). There was an evident
left-shift in the frequency distribution curve to lower blood
glucose levels (<5 mmol/l) after transplantation, and this was
reversed by the removal of the graft (Fig. 4D).
Figure 3. Daily blood glucose levels and metabolic parameters. (A) The mean fasting plasma glucose level 5.6 + 0.1 mmol/l pre-
transplantation was significantly dropped (***, P ¼ 0.0001) to 4.8 + 0.1 mmol/l post-transplantation, which was increased significantly
(****, P < 0.0001) after the removal of the graft, post-iridectomy to 6.3 + 0.1 mmol/l. (B) C-peptide was not detected in the aqueous humor
prior to transplantation but increased to 22.30 + 3.07 ng/dl (*, P < 0.05) while the graft was in place. After the removal of the graft, the C-
peptide level dropped to 0.94 + 0.54 ng/dl. C-peptide was not detected in the control, nontransplanted eye at any of the time points. (C)
The fructosamine level showed a decrease from 204.80 + 9.60 to 176.60 + 5.60 mmol/l after transplantation. (D) HbA1C level dropped
from 24.33 + 1.16 to 22 + 0.00 mmol/mol after transplantation, which was subsequently increased back to 25 mmol/mol at the end-point.
(The values are mean + SD.)
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C-peptide Levels Were Increased in the Aqueous
Humor of the Eye Where Islets Were Transplanted
C-peptide was not detected in the aqueous humor of both
eyes before transplantation. It was, however, significantly
increased in the transplanted eye to 22.30 +3.07 ng/dl (n
¼ 3 measurements; P < 0.05) while the graft was in place.
Following iridectomy, the aqueous humor C-peptide in the
transplanted eye was reduced to 0.94 + 0.54 ng/dl (n ¼ 3
measurements; Fig. 3B).
Long-Term Metabolic Parameters Showed Improved
Type-2 Diabetes in the Recipient Macaque Following
Intraocular Islet Transplantation
Fructosamine (glycosylated protein) level showed a decrease
from 204.8 + 9.60 mmol/l (n ¼ 3 measurements) pre-
transplantation to 176.6 + 5.60 mmol/l (n ¼ 3 measure-
ments) post-transplantation. It subsequently increased to
183.9 + 6.13 mmol/l (n ¼ 6 measurements) following graft
removal by iridectomy (Fig. 3C). We also observed a mea-
surable reduction in HbA1C (glycosylated hemoglobin)
levels from 24.33 + 1.16 mmol/mol (4.33% + 0.07%, n
¼ 3 measurements) pre-transplantation to 22 + 0.0 mmol/
mol (4.2% + 0.0%, n ¼ 3 measurements) post-
transplantation. At all time points during the post-
transplantation period, HbA1C remained at 22 mmol/mol
(4.2%), which is the minimum detection range of the assay.
After the graft removal by iridectomy, it eventually
increased to 25 mmol/mol (4.4%) at the end-point of the
experiment (Fig. 3D). The AUC of the blood glucose excur-
sion during IVGTTs showed that there was an improvement
of glucose tolerance after transplantation compared to
before transplantation, and this was reversed after the
iridectomy (Fig. 5).
Intraocular Islet Transplantation Associated with
Improved Lipid and Liver Profiles in the Type-2
Diabetic Macaque
Total cholesterol (TC) was slightly reduced after transplan-
tation from 3.53 + 0.41 mmol/l (n ¼ 4 measurements) to
3.27 + 0.23 mmol/l post-transplantation (n ¼ 3 measure-
ments) and this was subsequently increased to 4.22 + 0.43
Figure 4. Frequency distribution of fasting plasma glucose level. (A–C) A higher frequency of lower plasma glucose levels occurred during
the post-transplantation period compared to both pre-transplantation and post-iridectomy period. (D) There was a left shift in the
frequency distribution curve after transplantation, which was reversed after the removal of the graft. (A: Pre-Transplantation period, B:
Post-Transplantation period; C: Post-Iridectomy period; D: Frequency distribution curves)
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mmol/l (n ¼ 6 measurements) after the removal of the graft
by iridectomy. There was a small increase in plasma high-
density lipoprotein (HDL) after transplantation, whereas
low-density lipoprotein (LDL) was reduced by nearly 1
mmol/l while the graft was present. The plasma triglyceride
levels did not show any noticeable difference after trans-
plantation. There was no significant change in plasma ala-
nine transaminase and aspartate transaminase, suggesting
that liver damage did not occur at any stage of the proce-
dure (Table 1).
Discussion
Islet transplantation in type-1 diabetes patients is a promis-
ing therapeutic approach to achieve glycemic control, insulin
independence, and a higher quality of life5–7,9. One of the
major limitations with islet transplantation as a clinical treat-
ment strategy is the shortage of pancreatic donor islets and
the survival of the islet graft. These are the challenges for not
only type-1 diabetic patients but also insulinopenic type-2
diabetic patients where islet transplantation might be indi-
cated. We have suggested that islet transplantation to the
ACE (i.e., intraocular islet transplantation) may be a solution
to these problems12. We now showed for the first time that
transplantation of islets into the ACE of an early type-2
diabetic monkey improved the glycemic parameters and
reverted the progression of diabetes.
Following the intraocular islet transplantation, the mean
fasting blood glucose level in the type-2 diabetic macaque
was significantly lower, and this persisted until the removal
of the islet graft. Notably, this improvement in glycemic
control was lost after the removal of the graft by iridectomy.
In fact, removal of the graft resulted in even further
deterioration in glycemic control compared to pre-
transplantation, suggesting that the graft was preventing dia-
betes progression. Moreover, the macaque had an optimal
blood glucose level at <5 mmol/l more frequently during the
post-transplantation period (Fig. 4B). Together, these results
showed that the intraocular islet graft was able to maintain
glucose homeostasis. The positive outcome of islet trans-
plantation in the ACE of this type-2 diabetic macaque was
further corroborated by the improvements seen in its HbA1C,
fructosamine levels, and IVGTTs. These observed metabolic
improvements were likely the result of insulin production by
the intraocular islet graft, which was reflected by the sub-
stantial amount of C-peptide (*22 ng/ml) present in the
aqueous humor. We did not observe a significant increase
in the plasma/serum C-peptide levels after transplantation,
likely due to a substantial dilution of the C-peptide coming
from the intraocular islet graft. Interestingly, the observed
Figure 5. Intravenous glucose tolerance test (IVGTT). (A) IVGTT was performed by giving a 0.5 g/kg body weight bolus dose of glucose
intravenously, and the plasma glucose was assessed at predetermined intervals up to 90 min after the glucose injection. (B) The area under
the curve (AUC) showed improved glucose tolerance after islet transplantation, which was reversed by the removal of the graft.
Table 1. Lipids Profile and Liver Profile.
Parameters Normal value22,23 Pre-transplant (n ¼ 4) Post-transplant (n ¼ 3) Post-iridectomy (n ¼ 6)
Cholesterol (mmol/l) 2.15 + 0.02 3.53 + 0.41 3.27 + 0.23 4.22 + 0.43
HDL (mmol/l) 1.14 + 0.02 1.36 + 0.15 1.66 + 0.24 1.90 + 0.55
LDL (mmol/l) 0.85 + 0.02 2.12 + 0.27 1.41 + 0.13 2.25 + 0.34*
Triglycerides (mmol/l) 0.65 + 0.02 1.61 + 0.36 1.69 + 0.80 1.17 + 0.23
ALT (GPT) (IU/l) 48.58 + 26.64 56.50 + 10.75 48.67 + 5.03 49.13 + 36.02
AST (GOT) (IU/l) 42.62 + 11.75 46.50 + 9.95 39.67 + 5.51 46.86 + 19.70
The values are in mean + SD. *, P < 0.05, compared with post-transplantation. ALT: alanine transaminase; GPT: glutamic-pyruvic transaminase: AST: aspartate
transaminase; GOT: glutamic-oxaloacetic transaminase: LDL: low-density lipoprotein; HDL: high-density lipoprotein.
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benefits by the intraocular islet graft were maintained for 3
months after withdrawing the immunosuppression, consis-
tent with the previous findings of Abdulreda et al., showing
that tissue-specific immune tolerance can be established
with transient peri-transplantation immune intervention20,
although we did not examine immune tolerance here as it
was beyond the scope of the present study. It is also note-
worthy that there were no major ophthalmic complications
associated with transplanting a relatively high islet mass
(1,500 islet equivalents/kg) in this study.
Moreover, lipidemia is a common precursor for cardio-
vascular disease24,25, and it has been shown that TC and
LDL levels are inversely associated with beta cell function26.
Our findings showed improved lipid profiles following
intraocular islet transplantation in the recipient macaque
with high-fat-diet-induced type-2 diabetes (Table 1). It is
likely that the reduced TC and LDL levels following islet
transplantation further helped in improving beta cell func-
tion during the post-transplantation period. Therefore,
intraocular islet transplantation into patients with advanced
type-2 diabetes may offer benefits directly relevant to gly-
cemic control as well as diabetes-related complications.
In summary, the current preclinical findings in a macaque
with type-2 diabetes together with prior evidence in other
nonhuman primate models12,20 supported the clinical appli-
cation of pancreatic islet transplantation in the ACE as an
alternative to intra-hepatic islet transplantation not only in
type-1 diabetes patients but also in those with severe insulin-
dependent type-2 diabetes.
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